Polymorphic CAG repeats proposed as a potential missing genetic link in schizophrenia and bipolar disorder 

Schizophrenia and bipolar disorder have substantial genetic contributions, with twin studies estimating heritability at approximately 81%. However, genome-wide association studies (GWAS) have explained only a fraction of the inherited susceptibility, leaving a considerable proportion of genetic risk unexplained. A new hypothesis published in Genomic Psychiatry proposes that polymorphic CAG trinucleotide repeats, which have largely been overlooked in conventional genetic studies, could contribute to this missing heritability. 

CAG repeats are sequences of three DNA nucleotides that encode the amino acid glutamine. Abnormally expanded CAG repeats in individual genes are established causes of neurodegenerative disorders, including Huntington disease and several spinocerebellar ataxias. The proposed hypothesis extends this concept to psychiatric disorders, suggesting that the cumulative effects of moderately expanded CAG repeats across multiple genes could contribute to schizophrenia and bipolar disorder without necessarily causing neuronal death. 

The proposed framework identifies 45 candidate CAG-repeat genes, including ten associated with established repeat-expansion neurodegenerative disorders, three containing disease-associated repeats outside coding regions and 32 with moderately expanding repeats. Although previous research has suggested that tandem repeats in exons may account for approximately 4% of schizophrenia risk, the potential contribution of multiple polymorphic CAG-repeat genes remains insufficiently investigated. 

The proposed mechanism centres on astrocytes, which regulate neurotransmitter metabolism and provide neurons with glutamine, a precursor required for the synthesis of glutamate and gamma-aminobutyric acid (GABA). According to the hypothesis, increased expression of proteins containing expanded polyglutamine sequences could increase glutamine demand within astrocytes. To compensate, astrocytes may activate alternative metabolic pathways involving alpha-ketoglutarate and ammonia metabolism while retaining glutamine instead of supplying it to neurons. 

Consequently, reduced glutamine availability could impair neuronal production of glutamate, GABA and glutathione. Intracellular glutamine accumulation may also promote astrocytic swelling and reactive changes, potentially triggering inflammatory signalling, complement activation and synaptic elimination. Subsequent disruption of neuronal circuits could contribute to psychiatric manifestations. 

Differences in regional gene expression and receptor distribution are proposed to explain the distinct clinical presentations. N-methyl-D-aspartate (NMDA) receptor hypofunction is implicated in schizophrenia-related manifestations, whereas metabotropic glutamate receptor 5 signalling is proposed to contribute to bipolar disorder. 

Magnetic resonance spectroscopy (MRS) at 7 tesla offers improved differentiation between glutamate and glutamine compared with conventional lower-field imaging. A meta-analysis involving 28 studies, 647 patients and 608 controls reported increased glutamine and reduced glutamate concentrations in the medial frontal region in schizophrenia. Although these findings are compatible with the proposed metabolic framework, regional spectroscopy cannot establish whether the observed changes originate specifically from astrocytes or neurons. 

The hypothesis also proposes potential associations between repeat instability, genetic anticipation and differences in the age of psychosis onset. However, direct evidence linking expanded CAG repeats to astrocytic glutamine accumulation and subsequent neuroinflammation in schizophrenia and bipolar disorder remains limited. Findings involving the KCNN3 repeat have also shown inconsistent replication across populations. 

Further research involving repeat-aware genomic profiling, repeat-length analysis and single-cell transcriptomics is required to establish the proposed associations. If validated, this framework could improve understanding of psychiatric disease mechanisms and potentially support the development of molecular biomarkers and targeted therapeutic approaches. 

Reference  

  1. Hegde MV, Joshi AA, Badhe YS, Kale AA. Polymorphic CAG repeats and missing heritability in schizophrenia and bipolar disorder: a poly-glutamine neurodevelopmental hypothesis. Genomic Psychiatry. 2026. doi:10.61373/gp026p.0060. https://doi.org/10.61373/gp026p.0060. 

 

Don’t miss our updates!

We don’t spam! Read our [link]privacy policy[/link] for more info.

Leave a Reply